Evidence map›Paper›PMID 39779351›Full record

ArticleSaudi medical journal2025

Development and validation of a nomogram to predict survival after neoadjuvant chemotherapy in elderly women with triple-negative invasive ductal breast cancer: A SEER population-based study.

Ying Gao, Jinmiao Wang, Shoujun Wang, Weijie Tao, Ran Duan, Jie Hao, Ming Gao

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying GaoFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.
Jinmiao WangFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.
Shoujun WangFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.
Weijie TaoFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.
Ran DuanFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.
Jie HaoFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.ORCID https://orcid.org/0000-0002-2133-1146
Ming GaoFrom the Department of Breast and Thyroid Surgery (Y. Gao, J. Wang, S. Wang, Tao, Duan, Hao, M. Gao), Tianjin Union Medical Center, from the Department of Thyroid and Neck Oncology (Y. Gao), Tianjin Medical University Cancer Hospital, National Clinical Research Center for Malignant Tumors, Tianjin Clinical Research Center for Malignant Tumors, Tianjin Key Laboratory of Cancer Prevention and Treatment, and from the Medical College (J. Wang, S. Wang), Nankai University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo construct and verify a nomogram for post-neoadjuvant chemotherapy survival predication in elderly women with triple-negative invasive ductal breast cancer.

methodsElderly patients diagnosed as triple-negative invasive ductal breast cancer between 2019-2000 were screened from surveillance, epidemiology, and end results database. Depending on the post-neoadjuvant chemotherapy pathological response, they were assigned to the complete or non-complete response group. Inter-group clinicopathological characteristics and disease-specific and overall survivals were compared. Then, they were allocated randomly into the training or validation cohort. A prediction nomogram was developed in the training cohort and verified in the validation cohort.

resultsA total of 382 patients were included, with 285 patients in non-response group and 97 patients in response group. After propensity score matching, disease-specific survival showed a significant difference between response and non-response groups (88.7% versus 64.6%,

conclusionIn elderly women with triple-negative invasive ductal breast cancer, post-neoadjuvant chemotherapy pathological complete response could indicate improved disease-specific survival. A novel survival prediction nomogram was created to have satisfactory performance in these patients.

Indexed as

Neoadjuvant TherapyNomogramsSEER ProgramTriple Negative Breast NeoplasmsAgedAged, 80 and overCarcinoma, Ductal, BreastChemotherapy, AdjuvantFemaleHumansSurvival Ratedisease-specific survivalelderly patientsinvasive ductal carcinomaneoadjuvant chemotherapynomogramtriple-negative breast cancer

Identifiers

PMID39779351
PMCPMC11717112

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.